©2024 Stanford Medicine
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Not Recruiting
Trial ID: NCT00336765
Purpose
The purpose of this study is to assess the safety and tolerability of the multiple receptor
tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given
orally daily to adults with advanced solid tumors.
Official Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors
Stanford Investigator(s)
Heather Wakelee
Winston Chen and Phyllis Huang Professor
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- Subject has histologically confirmed malignancy that is metastatic or unresectable
- Subject has disease that is assessable by tumor marker, physical, or radiologic means
- Subject is at least 18 years old
- Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- Subject has a life expectancy ≥ 3 months
- Subject has normal organ and marrow function
- Subject gives written informed consent
- Subject must use an accepted method of contraception during the study
- Female subjects of childbearing potential must have a negative pregnancy test
Exclusion Criteria:
- Subject has received anticancer treatment within 30 days of first dose of XL647
- Subject has received another investigational agent within 30 days of first dose of
XL647
- Subject has known brain metastases
- Subject has corrected QT interval (QTc) of > 0.45 seconds
- Subject is currently receiving anticoagulation therapy with warfarin
- Subject has uncontrolled intercurrent illness
- Subject is pregnant or breastfeeding
- Subject has known HIV
Intervention(s):
drug: XL647
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joanne Fehling
6507361694